Pyrrolo[3,2-b]quinoxaline Derivatives as Types I1/2 and II Eph Tyrosine Kinase Inhibitors: Structure-Based Design, Synthesis, and in Vivo Validation.
Unzue, A., Dong, J., Lafleur, K., Zhao, H., Frugier, E., Caflisch, A., Nevado, C.(2014) J Med Chem 57: 6834
- PubMed: 25076195 
- DOI: 10.1021/jm5009242
- Primary Citation of Related Structures:  
4P4C, 4P5Q, 4P5Z - PubMed Abstract: 
The X-ray crystal structures of the catalytic domain of the EphA3 tyrosine kinase in complex with two type I inhibitors previously discovered in silico (compounds A and B) were used to design type I1/2 and II inhibitors. Chemical synthesis of about 25 derivatives culminated in the discovery of compounds 11d (type I1/2), 7b, and 7g (both of type II), which have low-nanomolar affinity for Eph kinases in vitro and a good selectivity profile on a panel of 453 human kinases (395 nonmutant) ...